# Study of SGN1 in Patients With Advanced Solid Tumor

> **NCT05038150** · PHASE1,PHASE2 · RECRUITING · sponsor: **Guangzhou Sinogen Pharmaceutical Co., Ltd** · enrollment: 70 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** SGN1

## Key facts

- **NCT ID:** NCT05038150
- **Lead sponsor:** Guangzhou Sinogen Pharmaceutical Co., Ltd
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-16
- **Primary completion:** 2028-01-18
- **Final completion:** 2028-08-31
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05038150

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05038150, "Study of SGN1 in Patients With Advanced Solid Tumor". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05038150. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*